Want to see CSTL full AI Analyst Report?
CSTL Stock Chart & Stats
$24.68
-$0.41(-1.68%)
At close: 4:00 PM EDT
$24.68
-$0.41(-1.68%)
Day’s Range― - ―
52-Week Range$14.59 - $44.28
Previous CloseN/A
Volume124.06K
Average Volume (3M)337.72K
Market Cap
$812.54M
Enterprise Value$508.81
Total Cash (Recent Filing)$266.81M
Total Debt (Recent Filing)$36.65M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding30,329,952
10 Day Avg. Volume322,460
30 Day Avg. Volume337,724
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.39
Price to Sales (P/S)3.28
P/FCF Ratio39.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.14Price Target Upside70.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.45
Revenue Forecast (FY)$352.38M
Bulls Say, Bears Say
Bulls Say
Sustained Test-volume Growth And Product MomentumConsistent, double-digit core volume growth (DecisionDx‑Melanoma/TissueCypher) indicates durable clinical adoption and expanding referral patterns. Sustained volume increases drive recurring service revenues, improve unit economics over time and support scaling of lab capacity and physician familiarity.
Conservative Balance Sheet And Ample LiquidityA large cash position and low leverage give strategic flexibility to fund clinical evidence generation, absorb reimbursement timing risks, invest in capacity, and pursue opportunistic M&A without immediate financing pressure, reducing solvency and execution risk.
High Gross Margins And Improved Cash GenerationSustained high gross margins and a clear pivot to positive operating and free cash flow demonstrate the business model's strong unit economics. Positive FCF provides internal funding for commercialization and evidence programs, supporting durable growth without persistent external capital.
Bears Say
Inconsistent Profitability And Return To Net LossesEarnings volatility and recent negative net income weaken return metrics and suggest operating leverage is still fragile. Recurring losses increase reliance on cash reserves for growth investments and can compress long‑term ROE until consistent profitability is reestablished.
Reimbursement And SCC Commercialization UncertaintyDelayed or unfavorable coverage decisions for DecisionDx‑SCC and slow reimbursement clarity for Advanced ADTx create structural revenue risk. Payer uncertainty can limit clinician adoption, extend sales cycles and materially delay expected future revenue contribution.
Rising Operating Expenses And Margin Pressure From InvestmentsSustained higher S&M, R&D and capacity-related costs (depreciation, lab supplies) can compress operating margins and delay leverage benefits from volume growth. If cost inflation persists, it could prolong negative adjusted EBITDA and make cash generation more cyclical.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $44.28 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $812.54M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Mar 04, 2027 which is in 215 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Jul 30, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.407 by $0.337.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 30,329,952 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.407. Following the earnings report the stock price went up 4.517%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.14 (70.76% Upside)
$42.14 (70.76% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 205.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
50.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.19%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum across core products—notably DecisionDx‑Melanoma and TissueCypher—with significant year‑over‑year test volume growth (36% core volumes; 58% TissueCypher) and an uplifted full‑year revenue guide. Profitability metrics improved versus prior year (narrower net loss, improved adjusted EBITDA) and the balance sheet remains solid with ~$261.7M in cash and marketable securities. Key negatives are an adjusted gross margin decline versus the prior comparable period, continued negative adjusted EBITDA (albeit improved), operating cash use in Q1, ongoing reimbursement and timing uncertainty for DecisionDx‑SCC and for broad commercialization of Advanced ADTx, and higher operating costs tied to growth and capacity investments. On balance, the positive commercial traction, raised guidance, improving profitability trends, and healthy liquidity outweigh the remaining execution and reimbursement risks.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$42.14
▲(70.76% Upside)
Technical Analysis
Ownership Overview
2.51% Insiders
16.30% Mutual Funds
2.08% Other Institutional Investors
64.37% Public Companies and
Individual Investors